title: [Antisense oligonucleotide targeting endostatin enhances hematopoiesis reconstitution in BMT mice].
abstract: OBJECTIVE
  To explore the effect of antisense oligonucleotide targeting endostatin (endostatin-ASON) transfecting bone marrow stromal cells ( BMSC) on hematopoiesis reconstitution in BMT mice.
  
  
  METHODS
  Inhibition of endostatin / VCAM-1 protein and mRNA expression was investigated by transfection of antisense oligonucleotide targeting endostatin with confocal microscopy, Western blot and RT-PCR. Bone marrow stromal cells were cultured and divided into 4 groups: group (1) without any treatment; group (2) BMT only; group (3) BMT + endostatin-ASON transfection; group (4) BMT + endostatin scrambled sequence transfection.
  
  
  RESULTS
  (1) Endostatin-ASON was successfully introduced into BMSC in vitro, and the transfecting rate was 86% ;(2) After Endostatin-ASON transfected into BMSC, the expression of Endostatin mRNA and its protein on the BMSC was signficantly inhibited at different time point after BMT [the grey value of Endostatin was (0.09 +/- 0.03) - (1.44 +/- 1.19) and (0.02 + 0.02) - (0.14 +/- 0.05), respectively] (P < 0.01 and P < 0.05); (3) Transfecting with Endostatin-ASON effectively promoted the expression of VCAM-1 mRNA and its protein on the BMSC [the gray value of VCAM-1 was (1.60 +/- 0. 92) - (8.05 +/- 0.87) and (0.07 +/- 0.02) - (0.67 +/- 0.09) , respectively] (P <0.01 and P <0.05) ; (4) There was no effects of transfecting Endostatin scrambled sequence on the expression of Endostatin and VCAM-1 on the BMSC (P > 0.05).
  
  
  CONCLUSIONS
  Endostatin-ASON could inhibit Endostatin expression and enhance VCAM-1 expression in BMSC after syngeneic-BMT in mice, which might be one of the mechanisms underlying the endostatin-ASON accelerating hematopoiesis reconstitution after allogeneic-BMT.
authors.affiliation: Department of Radiation Oncology, Shandong Tumer Hospital and Institute, Jinan 250117, China.
authors.forename: Ning
authors.initials: N
authors.lastname: Wu
authors.forename: Jie-lin
authors.initials: JL
authors.lastname: Qi
authors.forename: De-rong
authors.initials: DR
authors.lastname: Hu
authors.forename: Xi-qin
authors.initials: XQ
authors.lastname: Zhang
authors.forename: Bing
authors.initials: B
authors.lastname: Bu
authors.forename: Zhi-fang
authors.initials: ZF
authors.lastname: Liu
authors.forename: Han-ying
authors.initials: HY
authors.lastname: Sun
authors.forename: Wen-li
authors.initials: WL
authors.lastname: Liu
mesh_terms: D000818:Animals; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000378:metabolism; D016026:Bone Marrow Transplantation; D004305:Dose-Response Relationship, Drug; D043169:Endostatins / Q000096:biosynthesis* / Q000235:genetics; D005260:Female; D006410:Hematopoiesis; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis / Q000235:genetics; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D012333:RNA, Messenger / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection
chemical_list: D043169:Endostatins; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D018799:Intercellular Adhesion Molecule-1